MEDOMICS

Jiangsu Medomics Medical Technology Co., Ltd., founded in October 2017,is located at Biotech and Pharmaceutical Valley of the National Jiangbei New Area, Nanjing, Jiangsu Province. It is an international high-tech enterprise driven by innovation in the area of medical devices R&D, production and sales. Medomics focuses on diagnosis of microorganisms tumors and some rare diseases, mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and automatic instruments.

At the very beginning of COVID-19 on early 2020, Medomics developed lgM/lgG antibody detecting kit with the team of Zhong Nanshan, And Medomics published the first research paper on international journal together with State Key Laboratory of Respiratory Disease (National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health). The detecting kit was validated by CDC, Harvard Medical School and Columbia University Irving Medical Center etc. The kit has been exported to dozens of countries and areas, making great help against SARS-CoV-2.

At present, Medomics's series product of SARS-CoV-2 detection have been developed according to ISO 13485 Quality system and European CE Certification, as well as Australia TGA registration under the number :380739.

Million Source Limited is awarded to be a local responsible person since February, 2022.